Literature DB >> 26437777

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia.

W Zeijlemaker1, A Kelder1, Y J M Oussoren-Brockhoff1, W J Scholten1, A N Snel1, D Veldhuizen1, J Cloos1,2, G J Ossenkoppele1, G J Schuurhuis1.   

Abstract

Relapses after initial successful treatment in acute myeloid leukemia are thought to originate from the outgrowth of leukemic stem cells. Their flow cytometrically assessed frequency is of importance for relapse prediction and is therefore assumed to be implemented in future risk group profiling. Since current detection methods are complex, time- and bone marrow consuming (multiple-tubes approach), it would be advantageous to have a broadly applicable approach that enables to quantify leukemia stem cells both at diagnosis and follow-up. We compared 15 markers in 131 patients concerning their prevalence, usefulness and stability in CD34(+)CD38(-) leukemic stem cell detection in healthy controls, acute myeloid leukemia diagnosis and follow-up samples. Ultimately, we designed a single 8-color detection tube including common markers CD45, CD34 and CD38, and specific markers CD45RA, CD123, CD33, CD44 and a marker cocktail (CLL-1/TIM-3/CD7/CD11b/CD22/CD56) in one fluorescence channel. Validation analyses in 31 patients showed that the single tube approach was as good as the multiple-tube approach. Our approach requires the least possible amounts of bone marrow, and is suitable for multi-institutional studies. Moreover, it enables detection of leukemic stem cells both at time of diagnosis and follow-up, thereby including initially low-frequency populations emerging under therapy pressure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26437777     DOI: 10.1038/leu.2015.252

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  45 in total

1.  Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.

Authors:  A Venditti; F Buccisano; G Del Poeta; L Maurillo; A Tamburini; C Cox; A Battaglia; G Catalano; B Del Moro; L Cudillo; M Postorino; M Masi; S Amadori
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells.

Authors:  Liqing Jin; Kristin J Hope; Qiongli Zhai; Florence Smadja-Joffe; John E Dick
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

3.  A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.

Authors:  G G Wulf; R Y Wang; I Kuehnle; D Weidner; F Marini; M K Brenner; M Andreeff; M A Goodell
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

4.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

Authors:  M L Guzman; S J Neering; D Upchurch; B Grimes; D S Howard; D A Rizzieri; S M Luger; C T Jordan
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

5.  CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.

Authors:  Naoki Hosen; Christopher Y Park; Naoya Tatsumi; Yusuke Oji; Haruo Sugiyama; Martin Gramatzki; Alan M Krensky; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

6.  Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.

Authors:  Bijan Moshaver; Anna van Rhenen; Angèle Kelder; Marjolein van der Pol; Monique Terwijn; Costa Bachas; August H Westra; Gert J Ossenkoppele; Sonja Zweegman; Gerrit Jan Schuurhuis
Journal:  Stem Cells       Date:  2008-12       Impact factor: 6.277

7.  Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells.

Authors:  Marjolein A van der Pol; Nicole Feller; Marjet Roseboom; Bijan Moshaver; Guus Westra; Henk J Broxterman; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  Haematologica       Date:  2003-09       Impact factor: 9.941

8.  Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.

Authors:  Wolfgang Kern; Daniela Voskova; Claudia Schoch; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

9.  Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

Authors:  Gerrit J Schuurhuis; Michael H Meel; Floris Wouters; Lisa A Min; Monique Terwijn; Nick A de Jonge; Angele Kelder; Alexander N Snel; Sonja Zweegman; Gert J Ossenkoppele; Linda Smit
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

10.  Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Authors:  Monique Terwijn; Wendelien Zeijlemaker; Angèle Kelder; Arjo P Rutten; Alexander N Snel; Willemijn J Scholten; Thomas Pabst; Gregor Verhoef; Bob Löwenberg; Sonja Zweegman; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

View more
  35 in total

1.  The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.

Authors:  Leisi Zhang; Yong Zhou; Kai Chen; Pengcheng Shi; Yin Li; Manman Deng; Zhiwu Jiang; Xiangmeng Wang; Peng Li; Bing Xu
Journal:  Target Oncol       Date:  2017-10       Impact factor: 4.493

Review 2.  Minimal residual disease in acute myelogenous leukemia.

Authors:  N M Cruz; N Mencia-Trinchant; D C Hassane; M L Guzman
Journal:  Int J Lab Hematol       Date:  2017-05       Impact factor: 2.877

3.  Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.

Authors:  Nidhi Jyotsana; Amit Sharma; Anuhar Chaturvedi; Ramachandramouli Budida; Michaela Scherr; Florian Kuchenbauer; Robert Lindner; Fatih Noyan; Kurt-Wolfram Sühs; Martin Stangel; Denis Grote-Koska; Korbinian Brand; Hans-Peter Vornlocher; Matthias Eder; Felicitas Thol; Arnold Ganser; R Keith Humphries; Euan Ramsay; Pieter Cullis; Michael Heuser
Journal:  Ann Hematol       Date:  2019-05-18       Impact factor: 3.673

4.  Not just a marker: CD34 on human hematopoietic stem/progenitor cells dominates vascular selectin binding along with CD44.

Authors:  Dina B AbuSamra; Fajr A Aleisa; Asma S Al-Amoodi; Heba M Jalal Ahmed; Chee Jia Chin; Ayman F Abuelela; Ptissam Bergam; Rachid Sougrat; Jasmeen S Merzaban
Journal:  Blood Adv       Date:  2017-12-26

Review 5.  Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.

Authors:  Franklin Fuda; Weina Chen
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

6.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  Minimal residual disease and stem cell transplantation outcomes.

Authors:  Jacqueline Cloos; Gert J Ossenkoppele; Richard Dillon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  Universal monitoring of minimal residual disease in acute myeloid leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Sheila Shurtleff; Allen Eng-Juh Yeoh; Wee Joo Chng; Siew Peng Chen; Jeffrey E Rubnitz; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  JCI Insight       Date:  2018-05-03

9.  Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation.

Authors:  Johannes Frasez Soerensen; Anni Aggerholm; Gitte Birk Kerndrup; Marcus Celik Hansen; Ina Kathrine Lykke Ewald; Marie Bill; Lene Hyldahl Ebbesen; Carina Agerbo Rosenberg; Peter Hokland; Maja Ludvigsen; Anne Stidsholt Roug
Journal:  Blood Adv       Date:  2020-03-10

Review 10.  Flow Cytometric Minimal Residual Disease Analysis in Acute Leukemia: Current Status.

Authors:  Pulkit Rastogi; Man Updesh Singh Sachdeva
Journal:  Indian J Hematol Blood Transfus       Date:  2019-04-02       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.